The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025

NEW YORK, March 20, 2019 /PRNewswire/ -- Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025

Read the full report: https://www.reportlinker.com/p05741282/?utm_source=PRN

The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Further Key Findings From the Report Suggest:
• Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
• Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
• North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
• Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Read the full report: https://www.reportlinker.com/p05741282/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-cancer-immunotherapy-drug-discovery-outsourcing-market-size-is-projected-to-reach-usd-1-7billion-by-2025--300815687.html

SOURCE Reportlinker